SCHEMBL25786986

SCHEMBL25786986

CCn1ncc(-c2ccccc2Nc2cccc(C(F)(F)P)c2)c1C

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KCNK18 Q7Z418 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ YAP1 P46937 1/20 0.37
▸ TEAD4 Q15561 1/20 0.37
▸ TEAD2 Q15562 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ LMNA P02545 2/20 0.35
▸ TAS2R14 Q9NYV8 1/20 0.35
▸ CYP11B2 P19099 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25786834 0.82 KCNK18 (0.38) KCNK18MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL20552120 0.80 YAP1 (0.46) MEN1KMT2ASMN1; SMN2RAB9AALDH1A1
SCHEMBL20551966 0.78 YAP1 (0.49) MEN1KMT2AMAPTYAP1TEAD4
SCHEMBL20553653 0.77 YAP1 (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL25786811 0.73 KCNK18 (0.35) KCNK18SMN1; SMN2RAB9AALDH1A1GAA
SCHEMBL25786915 0.72 ABL1 (0.37) KMT2ARAB9AALDH1A1GAAMAPT
SCHEMBL25786802 0.71 HTT (0.41) MEN1KMT2ASMN1; SMN2MAPTYAP1
SCHEMBL25786862 0.70 SMN1; SMN2 (0.44) MEN1KMT2ASMN1; SMN2MAPTHTT
SCHEMBL20552900 0.70 ABL1 (0.38) MEN1KMT2ARAB9AGAAMAPT
SCHEMBL20552438 0.67 SMN1; SMN2 (0.46) MEN1KMT2ASMN1; SMN2RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 KCNK18 3394/4885MEN1 3125/4885KMT2A 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback